Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

CompletedOBSERVATIONAL
Enrollment

136

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
HR+/HER2- Breast CancerMetastatic DiseaseАdvanced Disease
Interventions
DRUG

Abemaciclib

Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)

DRUG

Abemaciclib

Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)

DRUG

Abemaciclib

Abemaciclib 200 mg orally every 12 hours

Trial Locations (1)

127051

Russian Society of Clinical Oncology, Moscow

All Listed Sponsors
collaborator

Russian Society of Clinical Oncology

UNKNOWN

lead

Blokhin's Russian Cancer Research Center

OTHER